# The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018, Regulation 3: Amendment of regulation 2 of the 2001 Regulations


In regulation 2(1) of the 2001 Regulations (interpretation) at the appropriate places insert—
““cannabis-based product for medicinal use in humans” means a preparation or other product, other than one to which paragraph 5 of part 1 of Schedule 4 applies, which—
(a) is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);
(b) is produced for medicinal use in humans; and—
(c) is—
(i) a medicinal product, or
(ii) a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product;”;
““clinical trial” has the same meaning as in the Medicines for Human Use (Clinical Trials) Regulations 2004;”;
““dronabinol” does not include any substance which—
(a) has the international non-proprietary name dronabinol (recommended by the World Health Organisation); and
(b) is derived from cannabis, cannabis resin or their constituents,
and stereoisomers of dronabinol are to be construed accordingly;; and”; and
““medicinal product” has the same meaning as in the Human Medicines Regulations 2012;”.

---
Source: https://www.legislation.gov.uk/uksi/2018/1055/regulation/3 (the official version)
Page: https://openlegislation.uk/misuse-of-drugs-amendments-cannabis-and-licence-fees-england-wales-and-scotland-regulations-2018/regulation-3
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

